Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2014

View Archived Issues

World MS Day: Recent innovations in stem cell therapies, small molecules and biomarkers

Tufts anti-PAR2 pepducin targeted at pulmonary hypertension

AZTherapies initiates trial of combination therapy in Alzheimer's disease

Abzena formed following PolyTherics and Antitope merger

Johnson & Johnson updates on its Medical Devices and Diagnostics business

BioInvent sells back ADC-1013 rights to Alligator Bioscience

Phase IIb study tests non-viral gene transfer for cystic fibrosis

Animal model of hypertriglyceridemia developed in zebrafish

Discovery and characterization of a small-molecule modulator of EBI2

Human iPS-endothelial cells overexpressing IL-8 receptors inhibit vascular injury

Amakem reports novel ROCK inhibitors

Bristol-Myers Squibb patents new HCV inhibitors

Novel PDE10A inhibitors disclosed by Allergan and Diaxonhit

Bionure's BN-201 promotes myelination in cell-culture assay

Cel-Sci expands phase III study of Multikine to new U.S. site

FDA grants orphan drug status to SAR-650984 for cancer

Norwegian investigators disclose new fusion proteins for allergic diseases

Daiichi Sankyo launches Efient in Japan for patients undergoing PCI

LG Life Sciences patents new FFA4 receptor agonists

Wellcome Trust grant supports Calibr's development of immunotherapy for prostate cancer

FDA issues complete response letter for MoxDuo

InterMune resubmits pirfenidone NDA to the FDA

FDA grants orphan drug designation to Advaxis' ADXS-cHER2 for osteosarcoma

Ganymed reports results from phase IIa gastroesophageal cancer trial

Daiichi Sankyo gains rights to lurasidone in four South American countries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...